Identification, validation and functional analysis of genes and miRNAs involved in recurrent non-small cell lung cancer.

肺癌治疗后复发率为20-85%。目前的预测工具是不准确的，因此患者接受通用治疗。我们的目的是确定与肺癌复发有关的基因。我们预计，这将转化为早期识别高危患者，从而实现个体化低毒性和更成功的治疗。我们也希望更好地了解肺癌复发的生物学，发现新的治疗靶点。

Recurrence of lung cancer after treatment affects 20-85% of patients. Current prognostication tools are inaccurate and thus patients receive generic treatments. Our intention is to identify genes involved in recurrence of lung cancer. We foresee that this will translate to earlier identification of at-risk patients enabling individualised less toxic and more successful treatments. We also hope to better understand biology of lung cancer recurrence and discover new targets for treatment.